Syncom Formulations Share Price Target 2026–2030 and What Drives It

Syncom Formulations share price today

Most people searching for the Syncom Formulations share price are looking at a number under ₹20 and trying to work out whether that is a cheap stock or simply a stock with a lot of shares. It is the second. Syncom Formulations (India) Limited was incorporated in 1988, is based in Indore and makes pharmaceutical formulations for India and for export markets. The low nominal price comes from a share count of roughly 94 crore, not from a distressed valuation.

At the 10 September 2026 research cut-off, Yahoo Finance showed a closing price of ₹19.41, market capitalisation of about ₹1,828 crore and trailing EPS of ₹0.86. That works out to about 22.6 times trailing earnings, and against a book value of ₹4.45 a share, roughly 4.4 times book. The quote above can move after publication; every ratio and scenario input below stays fixed to the stated cut-off.

The interesting tension is not the price level. It is that a company with a single-digit revenue growth rate is earning a return on capital employed near 27%, carrying almost no debt, and trading at a multiple that already assumes the profit line keeps outrunning the sales line. Whether it can is the question this article is built around.

What Syncom Formulations actually sells

The company describes three reported segments. Only one of them is the pharmaceutical business investors are usually thinking about, and the other two matter mainly because they sit inside the same consolidated revenue figure.

Reported segment	What it covers	Economic characteristic
Manufacturing and dealing in pharmaceutical drugs and formulations	Finished formulations across tablets, capsules, ointments, injections, liquid orals and effervescent forms	The core franchise; profitability depends on product mix and plant utilisation
Trading of commodities	Buying and selling goods outside the formulation line	Typically thin margin, and it can lift revenue without adding much profit
Renting of properties	Lease income from owned property	Small, stable, and unrelated to the drug business

Within the formulations segment the portfolio is broad rather than deep in any one specialty. That is common for an Indian formulations house of this size and it cuts both ways: a wide basket smooths demand across seasons and therapy cycles, but it rarely produces the pricing power that a concentrated, hard-to-make portfolio does.

Portfolio dimension	What the company lists
Anti-infective	Antibiotics and anti-infectives, anthelmintics, antimalarials
Chronic and specialty	Cardiac, gastro, gynae, ortho, ophthalmic and inhalers
Consumer-facing and paediatric	Derma, creams, gels, jelly, ORS, dry syrups and suspensions, paediatrics
Nutrition range	Life care, evolve and the right nutrition products under the Cratus brand
Dosage forms	Tablets, capsules, ointments, injections, liquid orals, effervescent

A product list is not a moat. What a list like this does tell you is where the operating leverage sits: with this many forms and therapy areas, utilisation of the manufacturing base is the swing factor in margin, and mix shifts can move profit far more than volume does.

The trailing-twelve-month picture

The most useful thing in the captured figures is the gap between how fast revenue grew and how fast profit grew.

Trailing-twelve-month measure	Reading	What it says
Revenue	₹498 Cr	Modest absolute scale for a listed formulations business
EBITDA	₹86 Cr	Cash operating profit before depreciation and financing
Operating margin	19.65%	Respectable for generic formulations, not premium-specialty territory
Profit margin	17.18%	Very little is lost between operating profit and net profit
Revenue growth, year on year	7.4%	Single-digit topline
Earnings growth, year on year	23.8%	Profit grew roughly three times faster than sales

That last pair is the whole story in two lines. Sales rose 7.4% while earnings rose 23.8%, which means the improvement came from margin, mix or cost, not from selling meaningfully more. The gap between profit margin of 17.18% and operating margin of 19.65% is unusually narrow — roughly ₹12 crore of about ₹98 crore of operating profit is absorbed by depreciation, interest and tax combined. With total debt of ₹1 crore, interest was never going to be a material line, so the narrowness rests mainly on a low effective tax charge that the captured figures do not explain. The tax note in the next annual report is the place to check it.

Margin-led earnings growth is real growth, and it is often the highest-quality kind while it lasts. It is also finite. A business cannot expand margin indefinitely, so at some point the 7.4% line has to move up if the 23.8% line is to be repeated. Reading the operating and net margin trend across future results is the single most informative thing an investor can do here; the quarterly results method sets out how to do it without getting distracted by the headline number.

A balance sheet with almost no debt

Balance-sheet measure	10 September 2026 reading	Why it matters
Total debt	₹1 Cr	Effectively unlevered
Cash and equivalents	₹113 Cr	Net cash of about ₹112 Cr after debt
Debt to equity	0.36%	Solvency is not a live question here
Return on capital employed	26.84%	Capital in the business is earning well

Two things follow. First, a return on capital employed near 27% on a near-debt-free balance sheet is a genuinely good number, because it is not being manufactured by leverage. Where debt is doing the work, a headline return figure flatters the operator; that distinction is worth understanding before comparing this company with a geared peer, and the debt-to-equity ratio guide covers the mechanics.

Second, ₹113 crore of cash against ₹498 crore of revenue is a large idle balance for a company this size. Cash is optionality, but it is also a drag on returns until it is deployed. What management does with it, whether capacity, a brand acquisition, a larger dividend or nothing, is a legitimate thing to watch, because at a 0.48% yield shareholders are clearly not being handed it back.

What the five-year growth record shows, and what was not captured

A year-by-year revenue and profit table was not captured for this company at the cut-off, so this article does not print one, and for the same reason there is no quarterly-results section here. Nothing has been reconstructed from memory to fill the gap. What is available is a set of Screener-derived long-period growth rates read on 5 August 2026, plus the trailing figures above.

Over five years, sales compounded at 14.73% and profit at 21.19%. That is a coherent picture as far as it goes: a business that grew sales in the mid-teens and grew profit faster because margin improved. The 26.84% return on capital employed is a current-period reading, not a five-year average, so it says where returns are now, not that they held up across the whole stretch. The 5 August and 10 September readings of that figure are numerically identical, which points to one carried-through number rather than two independent measurements, so it should not be treated as corroboration either.

It also frames the trailing year properly. Revenue growth of 7.4% is roughly half the five-year sales CAGR, while earnings growth of 23.8% is a little ahead of the five-year profit CAGR. In other words the recent period leaned harder on margin than the five-year average did. One year is not a trend, but it is the reason the growth assumptions later in this article sit below the historical profit CAGR rather than on it.

How the Syncom Formulations share price has moved

The stock has re-rated sharply in a short window, which is important context for anyone arriving at the current price.

Price measure	5 August 2026, Screener-derived	10 September 2026, Yahoo Finance
Market capitalisation	₹1,264 Cr	₹1,828 Cr
52-week high	₹18.27	₹21.39
52-week low	₹10.30	₹10.30
Distance below the 52-week high	-26.4%	-9.26%

Market capitalisation rose about 45% in roughly five weeks, and the 52-week high moved from ₹18.27 to ₹21.39, meaning the shares set new highs during that stretch. The 52-week low of ₹10.30 is unchanged, so the full one-year range runs from about ₹10.30 to ₹21.39. A stock that has roughly doubled off its low and now sits 9.26% below its high is not being bought quietly.

That matters for expectations. When a multiple expands faster than earnings, a good deal of the next few years of profit growth has already been paid for. The valuation framework below therefore deliberately tests what happens if the multiple does not hold.

Valuation at the research cut-off

Valuation measure	10 September 2026 reading	Interpretation
Closing price	₹19.41	Fixed research input, not a live figure
Market capitalisation	₹1,828 Cr	Small enough that liquidity and disclosure depth matter
Trailing EPS	₹0.86	Yahoo Finance trailing basis
Recalculated P/E	22.57×	Price divided by trailing EPS
Reported P/E	22.62×	Rounding difference only
Book value per share	₹4.45	Implies price to book near 4.37×, a premium the near-27% return on capital earns on a near-debt-free base
Dividend yield	0.48%	Not an income holding
Promoter holding	50.57%	Majority control retained

Roughly 22.6 times trailing earnings is neither cheap nor extreme for an Indian formulations company earning 27% on capital with net cash. Whether it is reasonable depends almost entirely on the growth question already identified: at mid-teens earnings growth the multiple is defensible, at 7% it is not. Readers less comfortable with what a P/E does and does not capture will find the P/E ratio explained useful before reading the scenarios.

One structural caveat. Promoters hold 50.57%, which leaves about 49.43% with everyone else, but the split of that free float between domestic institutions, foreign investors and retail holders was not part of the captured figures. Institutional ownership is often thin in companies of this size, and thin institutional ownership tends to mean wider price swings and less analytical scrutiny than a larger name receives.

Valuation framework

The scenario model starts with TTM EPS of ₹0.86. For each year it applies EPS_TTM × (1 + growth)^(year − 2026 + 112/365) × exit P/E, then rounds the result to the nearest ₹1. The 112/365 factor represents the fraction of the first forecast year remaining from 10 September to 31 December. Dividends are excluded.

Scenario	Annual EPS growth	Exit P/E	Business interpretation
Bear	8%	14×	Margin gains stop, growth settles near the recent 7.4% topline rate and the multiple de-rates toward a plain generics rating
Base	13%	20×	Volume growth returns toward the five-year sales trend, margin holds, and the multiple settles a little below today’s rating
Bull	18%	27×	Mix improves, the cash pile is deployed productively, and returns on capital keep the multiple modestly above today’s

The growth rates are set below the five-year profit CAGR of 21.19% on purpose. A company that compounded profit at 21% for five years, mostly through margin expansion, is unlikely to repeat that for five more from a higher base. The multiples are anchored below-to-around the current 22.57×: the bear case tests a clear de-rating, the base case a mild one, and the bull case allows only a modest premium. Assuming both perfect growth and permanent multiple expansion would just restate the enthusiasm already visible in the five-week move above. These are scenarios, not probability-weighted forecasts, and the general method behind them is set out in how to value a stock.

Syncom Formulations share price target 2026 to 2030

The grid above is generated only from the disclosed EPS, growth and exit-P/E inputs. It does not model a fresh share issue, a bonus or split, an acquisition, a change in the segment mix, export or currency effects, regulatory action at a manufacturing site, or a shift in capital structure. It also assumes the trailing EPS of ₹0.86 is a fair starting point; if a future result resets that base materially, the whole grid has to be rebuilt rather than adjusted.

Risks that can break the thesis

The first risk is the one the numbers already point at: earnings growth that came mainly from margin, on top of 7.4% revenue growth, is not the same as durable compounding. If margin stops improving and volume does not accelerate, earnings growth converges toward the topline rate and the multiple has little support.

The second is valuation compression after a fast move. A re-rating of the speed described above, in a company of this size, can reverse just as quickly, and profits can keep growing while the share price does not. Nothing in the five-week move told an investor that the underlying earnings had changed; what changed was the price the market was willing to pay for them.

The third is disclosure depth. No year-by-year financial table and no quarterly series were captured here, promoter pledge data was not available, and the free float composition is unknown. That is not evidence of a problem, but it does mean an investor is working with less information than they would have on a large-cap, and should go to the filings directly rather than rely on a summary.

The fourth is sector-specific. Formulations manufacturing depends on regulatory inspections, plant approvals, price controls on scheduled drugs and raw material costs, principally imported intermediates. Any of these can compress a 19.65% operating margin quickly, and a single adverse inspection outcome can cost a facility its ability to supply a market.

What would change the thesis

The picture strengthens if revenue growth moves back toward the five-year sales CAGR of 14.73% while the operating margin holds near current levels, because that would show earnings growth coming from the business expanding rather than from cost control. Productive deployment of the ₹113 crore cash balance, into capacity or a portfolio that raises the return on capital rather than diluting it, would also help. So would a rising dividend, which at 0.48% is currently close to symbolic.

It weakens if the operating margin falls while revenue growth stays in single digits, if the commodity trading segment starts contributing a larger share of revenue and drags blended margin down, if return on capital employed drifts away from the high-20s, or if working capital starts absorbing the cash that the profit and loss account is reporting. Any regulatory action at a manufacturing site would require a full reassessment regardless of the model.

Quarterly monitoring scorecard

Question	Constructive evidence	Warning sign
Is growth returning to the topline?	Revenue growth moves above 10% year on year	Revenue stays near or below the recent 7.4%
Is margin the whole story?	Profit growth tracks revenue growth more closely	Earnings keep outrunning sales on margin alone
Is the mix improving?	Formulations grow faster than commodity trading	Trading revenue rises as a share of the total
Is capital still earning?	Return on capital employed holds near 26.8%	ROCE falls as the asset or cash base grows
Is the cash being used?	A stated plan for the ₹113 Cr balance	Cash builds up year after year with no deployment and no payout
Is disclosure improving?	Segment revenue and margin reported consistently	Consolidated figures only, with no segment detail

What the figures do and do not settle

The captured figures settle several things clearly. Syncom Formulations is profitable, carries essentially no debt, holds ₹113 crore in cash, earns close to 27% on capital employed, and is majority-owned by its promoters. On those measures it is a sounder business than a sub-₹20 share price would lead a casual observer to assume.

What they do not settle is the growth question, and that is the one the current valuation depends on. Revenue rose 7.4% in the trailing year against a five-year sales CAGR of 14.73%, while the share re-rated hard. A 22.57× multiple can be justified by 27% returns on capital and mid-teens growth; it is harder to justify by 27% returns and single-digit growth. The evidence that would resolve it is not a new product announcement but two or three results showing volume, rather than margin, doing the work. Anyone building a wider view of the sector can compare this against larger and better-covered pharma names using the fundamental analysis method.

FAQ

What is the Syncom Formulations share price target for 2026?

The 2026 figures in the grid above come from the trailing EPS of ₹0.86, three earnings-growth rates and three exit P/E multiples, applied only to the 112 days remaining in the year from 10 September. Because that partial year is short, the growth rate barely moves the 2026 figures — it contributes only about 2% to 5% of compounding. Almost the entire spread between the three 2026 outcomes comes from the exit multiple, which ranges from 14× to 27×. They are a range of outcomes, not a promised price.

What is the Syncom Formulations share price target for 2030?

The 2030 column compounds the same starting EPS across roughly four and a quarter years at each scenario’s growth rate, then applies that scenario’s exit P/E. The spread between the bear and bull columns is wide by 2030 because both the growth rate and the multiple differ, and small changes in either compound into large differences over that horizon. It should be read as a sensitivity exercise, not a forecast.

What does Syncom Formulations do?

It manufactures, markets and sells pharmaceutical formulations in India and internationally, across anti-infectives, cardiac, gastro, derma, gynae, ortho, ophthalmic, paediatric and nutrition ranges, in dosage forms including tablets, capsules, ointments, injections, liquid orals and effervescent products. It also reports a commodity trading segment and a property rental segment. Incorporated in 1988, it is based in Indore.

Who are the promoters of Syncom Formulations?

Promoter holding stood at 50.57% at the 10 September 2026 cut-off, which is a majority stake. The composition of the remaining 49.43% between institutional and retail holders was not part of the captured figures, and pledge data was not available either. Both are worth checking directly in the latest shareholding pattern filed with the exchange.

Is Syncom Formulations listed on NSE or BSE?

The figures in this article are taken from the NSE line, under the symbol SYNCOMF. Listing status on other exchanges was not part of the captured data, so confirm it from the exchange records before assuming where you can trade it. The company’s filings and quote page on NSE are linked in the sources below.

How has the Syncom Formulations share price moved historically?

Over the trailing 52 weeks the shares ranged between ₹10.30 and ₹21.39, so the high is more than double the low. Between the 5 August and 10 September 2026 readings, market capitalisation rose from ₹1,264 crore to ₹1,828 crore, or about 45%, and the 52-week high moved up from ₹18.27 to ₹21.39. At ₹19.41 the stock was 9.26% below its high.

Related research

• P/E Ratio Formula: what a multiple does and does not capture
• How to Value a Stock: the method behind the scenarios above
• Debt-to-Equity Ratio: reading a balance sheet like this one
• How to Read Quarterly Results in 15 Minutes
• Fundamental Analysis of Stocks: a practical Indian guide
• Caplin Point Labs share price target
• Natco Pharma share price target
• Vikram Thermo share price target

Sources and methodology

• Syncom Formulations on Screener.in
• Syncom Formulations quote and filings on NSE
• Syncom Formulations company website

Price, 52-week range, market capitalisation, trailing EPS, book value, the P/E and price-to-book ratios, debt, cash, revenue, EBITDA, margins, the year-on-year growth rates, dividend yield, promoter holding and the business description were captured from Yahoo Finance after the completed 10 September 2026 session. The five-year sales and profit CAGRs, the return on capital employed figure and the comparison column dated 5 August 2026 are Screener-derived. No year-by-year financial table and no quarterly series were captured for this company, so none is printed here and none has been reconstructed. Analytical judgment begins with the reading of the margin-led earnings growth, the scenario growth rates and exit multiples, the risk discussion and the monitoring questions; those are interpretation, not reported data.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. The scenarios are illustrations, not guarantees. Verify current exchange filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.